Caxton Associates LLP Syndax Pharmaceuticals Inc Transaction History
Caxton Associates LLP
- $2.87 Trillion
- Q1 2025
A detailed history of Caxton Associates LLP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Caxton Associates LLP holds 20,945 shares of SNDX stock, worth $187,457. This represents 0.01% of its overall portfolio holdings.
Number of Shares
20,945Holding current value
$187,457% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding SNDX
# of Institutions
241Shares Held
101MCall Options Held
1.36MPut Options Held
618K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$76.3 Million8.82% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$70.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.87MShares$43.6 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.21MShares$37.7 Million5.73% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.01MShares$35.9 Million0.12% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $506M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...